Esperion Net Debt vs Property Plant And Equipment Net Analysis
ESPR Stock | USD 2.30 0.12 5.50% |
Esperion Therapeutics financial indicator trend analysis is much more than just examining Esperion Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Esperion Therapeutics is a good investment. Please check the relationship between Esperion Therapeutics Net Debt and its Property Plant And Equipment Net accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.
Net Debt vs Property Plant And Equipment Net
Net Debt vs Property Plant And Equipment Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Esperion Therapeutics Net Debt account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have weak relationship.
The correlation between Esperion Therapeutics' Net Debt and Property Plant And Equipment Net is 0.39. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of Esperion Therapeutics, assuming nothing else is changed. The correlation between historical values of Esperion Therapeutics' Net Debt and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Esperion Therapeutics are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Net Debt i.e., Esperion Therapeutics' Net Debt and Property Plant And Equipment Net go up and down completely randomly.
Correlation Coefficient | 0.39 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most indicators from Esperion Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.As of 05/16/2024, Selling General Administrative is likely to drop to about 64.1 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 25.1 M
2023 | 2024 (projected) | Interest Income | 4.0M | 3.5M | Reconciled Depreciation | 250K | 432.3K |
Esperion Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Esperion Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Esperion Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 214.4M | 353.3M | 381.6M | 247.9M | 205.8M | 181.9M | |
Other Current Liab | 34.6M | 37.8M | 48.7M | 65.4M | 62.7M | 65.9M | |
Total Current Liabilities | 66.1M | 94.1M | 73.4M | 92.3M | 156.2M | 164.0M | |
Total Stockholder Equity | (695.3M) | (838.8M) | (1.1B) | (1.3B) | (455.0M) | (432.2M) | |
Property Plant And Equipment Net | 2.7M | 7.3M | 2.6M | 1.2M | 4.7M | 4.9M | |
Net Debt | (164.6M) | (119.6M) | 51.3M | 136.2M | 458.7M | 481.6M | |
Retained Earnings | (695.3M) | (838.8M) | (1.1B) | (1.3B) | (1.5B) | (1.5B) | |
Accounts Payable | 28.9M | 52.0M | 17.6M | 23.0M | 31.7M | 33.3M | |
Cash | 166.1M | 305.0M | 208.9M | 124.8M | 82.2M | 91.3M | |
Non Current Assets Total | 2.7M | 7.4M | 52.6M | 1.3M | 4.7M | 4.5M | |
Cash And Short Term Investments | 166.1M | 305.0M | 208.9M | 124.8M | 82.2M | 91.8M | |
Common Stock Shares Outstanding | 27.1M | 27.5M | 28.9M | 66.4M | 103.1M | 108.3M | |
Liabilities And Stockholders Equity | (500.8M) | (389.4M) | (527.8M) | (768.3M) | 205.8M | 216.1M | |
Non Current Liabilities Total | 128.4M | 355.3M | 505.2M | 479.4M | 504.6M | 529.8M | |
Other Current Assets | 10.9M | 24.8M | 62.8M | 9.9M | 4.7M | 8.6M | |
Other Stockholder Equity | (50K) | (26K) | (30K) | (73K) | 1.1B | 1.1B | |
Total Liab | 194.5M | 449.4M | 578.5M | 571.7M | 660.8M | 693.8M | |
Property Plant And Equipment Gross | 2.7M | 7.3M | 664K | 164K | 6.7M | 7.0M | |
Total Current Assets | 211.7M | 345.9M | 329.0M | 246.7M | 201.1M | 160.4M | |
Accumulated Other Comprehensive Income | (845K) | (319K) | 23K | 0.0 | (31K) | (2K) | |
Non Currrent Assets Other | (34.7M) | (7.4M) | 50M | (42.1M) | (1.0) | (1.05) | |
Short Term Investments | 165.7M | 99.1M | 34.7M | 0.0 | 50.4M | 42.1M | |
Property Plant Equipment | 1.1M | 1.3M | 664K | 164K | 188.6K | 179.2K | |
Net Tangible Assets | 19.9M | (96.2M) | (196.9M) | (323.8M) | (291.4M) | (276.8M) | |
Retained Earnings Total Equity | (695.3M) | (838.8M) | (1.1B) | (1.3B) | (1.2B) | (1.1B) | |
Capital Surpluse | 715.2M | 797.7M | 964.4M | 1.1B | 1.2B | 676.3M | |
Long Term Investments | 34.7M | 0.0 | 50.4M | 42.1M | 37.9M | 29.2M | |
Net Invested Capital | 20.0M | 83.2M | 61.3M | (63.9M) | (193.4M) | (183.7M) |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Esperion Stock analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Esperion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Revenue Per Share 1.128 | Quarterly Revenue Growth 0.714 | Return On Assets (0.43) | Return On Equity (2.61) |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Esperion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.